From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

Slides:



Advertisements
Similar presentations
9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.
Advertisements

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:
PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.
HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International.
HIV Prevention Programs Among Older Adult Populations
The Combined Approach to Preventing HIV Infection Robin Shattock, Mitchell Warren, Sheena McCormack, Catherine Hankins,
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.
Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.
INA-RESPOND Test and Treat Study
Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.
How well are we doing in preventing HIV and how can we do better?
P REPARING FOR P RE P: FROM THEORY TO PRACTICE K EY POPULATIONS Dr Oscar Radebe.
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
Methods for Estimating Global Resource Needs for HIV/AIDS John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
The potential and challenges of ARV-based HIV prevention: An overview
Washington D.C., USA, July 2012www.aids2012.org Implementation Science: Realizing the HIV Prevention Revolution Nelly R. Mugo, MD, MBChB, MMed, Kenyatta.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Introduction to HIV New Prevention Technologies (NPTs)
Topical, Oral; Daily, Intermittent; Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of.
Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
State of the Art: Epidemiology and Access
Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
Washington D.C., USA, July 2012www.aids2012.org Summary of Track C: Epidemiology and Prevention Science Audrey Pettifor, UNC Christopher Hurt, UNC.
Resource Needs Model Rachel Sanders October 28 th, 2010.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
Pro Vice-Chancellor (Research), University of KwaZulu-Natal Director: CAPRISA - Centre for the AIDS Programme of Research in SA Professor in Clinical Epidemiology,
Controlling the epidemic_17Jul11 Controlling the epidemic Clinical considerations – design, set-up and conduct Sheena McCormack.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.
AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.
INVESTING TO END THE AIDS EPIDEMIC: A NEW ERA FOR HIV RESEARCH & DEVELOPMENT HIV VACCINES WORKING GROUP & MICROBICIDES RESOURCE TRACKING E. Donaldson 1,
IAS Policy and Advocacy priority on Treatment as Prevention Carlos F. Cáceres Multidisciplinary Research on ARV-based Prevention 30 June 2013 Kuala Lumpur.
Ethics in a new era Microbicides 2012 Preconference Bridget Haire.
Standard of prevention: a qualitative study of principal investigators’ perspectives Bridget Haire.
How Can Civil Society Measure Value for Money and Prove Its Worth? Amanda Glassman Center for Global Development July 26, 2012.
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
Microbicides and PrEP: Back to Basics Wednesday July 25, 2012 ADM Kashuba.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Ending the AIDS epidemic: Science, Policy and Community Peter Godfrey-Faussett UNAIDS, Geneva.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,
New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
Advances in Biomedical HIV Prevention Interventions
New Prevention Technologies Workshop Module 2: NPTs in context
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
The Uganda Country Presentation EAC Think Tank on HIV Prevention 24th to 26 th February 2009 Laico Regency Hotel, Nairobi, Kenya Republic of UgandaUganda.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
STATE OF THE EPIDEMIC AND THE RESPONSE PROMISES, PROGRESS AND PROBLEMS DR. ALEX COUTINHO MD MPH Executive Director Infectious Diseases Institute.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
Session: Treatment is Prevention? 16 th International Conference on AIDS and Sexually Transmitted Infections in Africa, Addis Ababa, Ethiopia Catherine.
IAS Satellite Session 25th July 2017 Daniel Were, PhD
20:20 Vision Making new and old money work better
Pre-exposure Prophylaxis (PrEP)
PrEP: A Case-by-Case Approach
Setting the Stage for PrEP Where are we now, and where should we go?
Global Optimization of the Response to HIV
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
Presentation transcript:

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome

Timing is Everything  2004  2007  2010  2011

1.No magic bullet; need smart combinations

Female Condoms Felblum P, AIDS 2001 Male Condoms Brody S, NEJM 1996 Note: PMTCT, Screening transfusions, Harm reduction, Universal precautions, etc. have not been included – this is focused on reducing sexual transmission Behavioural Intervention -Abstinence -Be Faithful HIV Counselling and Testing Coates T, Lancet 2000 Treatment of STIs Grosskurth H, Lancet 2000 Male circumcision Auvert B, PloS Med 2005 Gray R, Lancet 2007 Bailey R, Lancet 2007 Microbicides for women Abdool Karim Q, Science 2010 Treatment for prevention Donnell D, Lancet 2010 Cohen M, 2011 Positive prevention - behavioral Fisher J, JAIDS 2004 Grant R, NEJM 2010 Pre-Exposure prophylaxis Oral PrEP for MSM Post Exposure prophylaxis (PEP) Scheckter M, 2002 Vaccines Rerks-Ngarm S, NEJM 2009 COMBINATION HIV PREVENTION

Study Effect size (CI) Medical male circumcision (Orange Farm, Rakai, Kisumu) 57% (42, 68) Prime-boost Vaccine (Thai RV144) 31% (1, 51) Efficacy 0% % TDF/FTC oral-PrEP (iPrEx, Grant et al 2010) 44% (15, 63) 1% tenofovir gel (CAPRISA 004) 39% (6, 60) Immediate ART for positive partners (HPTN052) 96% (82, 99) TDF/FTC oral-PrEP (TDF2, CDC) TDF oral-PrEP (Partners PrEP) 63% (22, 83) TDF/FTC oral-PrEP (Partners PrEP) 62% (34, 78) 73% (49, 85)

History Lessons A vaccine [or condom, or microbicide or tablet] that sits on the shelf is useless. Albert Sabin

0% 20% 40%60%80%100% 10-12% Adults with access to HIV testing in Africa 8% Harm reduction for injection drug users 33% Prevention of mother-to-child transmission 9% Condom access 11% Behavior change programs for men who have sex with men 16% Behavior change programs for commercial sex workers And an Old Challenge  Can we deliver on the promise?  Global access to existing prevention options Source: UNICEF/UNAIDS/WHO 2009

1.No magic bullet; need smart combinations a)Corollary: Need smart researchers, policy makers, funders and advocates!

1.No magic bullet; need smart combinations 2.It’s behaviour

1.No magic bullet; need smart combinations 2.It’s behaviour 3.Adherence, adherence, adherence

1.No magic bullet; need smart combinations 2.It’s behaviour 3.Adherence, adherence, adherence 4.Embrace the niche

1.No magic bullet; need smart combinations 2.It’s behaviour 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence

Pathway to Reversing the Epidemic Male & Female Condoms ARV microbicide Partially effective vaccine highly effective vaccine Time HIV incidence ARV PrEP Medical Male Circumcision ARV Tx as Px Deliver today Deliver soon Develop for tomorrow Demonstrate today

1.No magic bullet; need smart combinations 2.It’s behaviour, stupid! 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence 6.Testing, testing, testing

1.No magic bullet; need smart combinations 2.It’s behaviour, stupid! 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence 6.Testing, testing, testing 7.Watch our language

An Evolving Lexicon  ART  ARV  Oral PrEP  PEP  Topical PrEP  Microbicides  Long-acting methods  TasP  TisP  T4P  TnT  TLC+

1.No magic bullet; need smart combinations 2.It’s behaviour, stupid! 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence 6.Testing, testing, testing 7.Watch our language 8.Four questions

Four Questions  Who needs what?  Who wants what?  Who gets what?  Who pays?

1.No magic bullet; need smart combinations 2.It’s behaviour, stupid! 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence 6.Testing, testing, testing 7.Watch our language 8.Four questions 9.Money, money, money

Money, Money, Money  “Science of Prioritization and the Primacy of Targeting” Ward Cates, personal communication, the day before yesterday  “Substantial changes are needed to achieve a more targeted and strategic approach to investment in the response to the HIV/AIDS epidemic that will yield long-term dividends.” Towards an improved investment approach for an effective response to HIV/AIDS, Schwartländer B et al, Lancet, 3 June 2011  “If one accepts the tenet that science should inform policy, then the scientific data are speaking loud and clear. Global policy- makers must seriously consider these new data in their priority- setting and decision-making.” AIDS: Let Science Inform Policy, Fauci AS, Science, 1 July 2011

1.No magic bullet; need smart combinations 2.It’s behaviour, stupid! 3.Adherence, adherence, adherence 4.Embrace the niche 5.Strategize the sequence 6.Testing, testing, testing 7.Watch our language 8.Money, money, money 9.Four questions 10.Scientific data do not change the world— programmes and policies backed by civil society, donors, implementers and governments do

Reading List, July 2011  AIDS: Let Science Inform Policy, Fauci AS, Science, 1 July 2011  Antiretroviral Prophylaxis: A Defining Moment in HIV Control, Abdool Karim SA and Abdool Karim Q, Lancet, 15 July 2011  Towards an improved investment approach for an effective response to HIV/AIDS, Schwartländer B et al, Lancet, 3 June 2011  We CAN End The Epidemic,

WITH URGENCY